Pegloticase-Induced Rapid Uric Acid Lowering and Kidney and Cardiac Health Markers in Youth-Onset Type 2 Diabetes: A Pilot Clinical Trial
To the Editor:Young persons with youth-onset type 2 diabetes (T2D), particularly males, are disproportionately affected by hyperuricemia compared with peers without diabetes and those with type 1 diabetes (T1D). 1 Research on the effects of reductions in SUA levels on kidney and cardiovascular outcomes in youth-onset T2D is limited.Existing trials have primarily focused on xanthine oxidase inhibitors, achieving SUA level reductions of 1-4 mg/dL, which may not significantly affect cardio-renal outcomes. [2][3]][4] Uricases like rasburicase and pegloticase rapidly break down uric acid into the water-soluble allantoin. 5This pilot trial aimed to determine the impact of rapid and substantial lowering of SUA levels with pegloticase on markers of kidney and cardiovascular health in young adult men with T2D. METHODSWe conducted an open-label, non-placebo-controlled pilot trial, recruiting young adult men from diabetes clinics at the University of Colorado Hospital and Children's Hospital Colorado.The trial (registration number NCT03899883) was approved by the Colorado Multiple Institutional Review Board.All participants provided written informed consent.
Authors
- Richard J. Johnson (ORCID: https://orcid.org/0000-0003-3312-8193)
- Kristen J. Nadeau (ORCID: https://orcid.org/0000-0002-0477-3356)
- Amy Rydin (ORCID: https://orcid.org/0000-0003-2607-1950)
- Laura Pyle
- Vuddhidej Ophascharoensuk (ORCID: https://orcid.org/0000-0002-6041-7989)
- Ye Ji Choi (ORCID: https://orcid.org/0000-0002-0167-175X)
- Daniel van Raalte
- Phoom Narongkiatikhun (ORCID: https://orcid.org/0000-0002-1569-4581)
- Petter Bjornstad (ORCID: https://orcid.org/0000-0002-5160-2947)
- Callie Rountree-Jablin
- Kalie L. Tommerdahl (ORCID: https://orcid.org/0000-0003-1132-1574)
- Lorna P. Browne
- Alyssa Caldwell‐McGee (ORCID: https://orcid.org/0009-0006-5944-7458)
- Sungho Park
- Alex J. Barker (ORCID: https://orcid.org/0000-0002-6283-9157)
- Lynette Driscoll
- Maureen Pushea
- Jo Ann V. Antenor
Institutions
- Ascension (US)
- Colorado School of Public Health (US)
- University of Washington (US)
- Horizon Therapeutics (United States) (US)
- Children's Hospital Colorado (US)
- Dell Children's Medical Center of Central Texas (US)
- Amsterdam University Medical Centers (NL)
- Rocky Mountain MS Center (US)
- Chiang Mai University (TH)
- University of Colorado Anschutz Medical Campus (US)
- University of Colorado Denver (US)
Publication Details
- Journal
- Kidney Medicine
- Published
- 2024-10-09
- DOI
- https://doi.org/10.1016/j.xkme.2024.100911
- Citations
- 3
- Primary Topic
- Gout, Hyperuricemia, Uric Acid
- Type
- article
- Field-Weighted Citation Impact
- 1.02
Funders
- Horizon Pharma
- Colorado Clinical and Translational Sciences Institute